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Letter to the Editor
Frequency  of  adverse  events associated  to
antiretroviral drugs  in patients  starting  therapy  in
Salvador, Brazil
Table 1 – Frequency of main (>5%) adverse events
associated with the ﬁrst antiretroviral regimen.
Adverse event Frequency (n = 212)
Neurological 59 (27.8%)
Dizziness 26 (44%)
Insomnia 18 (30.5%)
Depression 8 (13.5%)
Gastrointestinal 44 (20.8%)
Nausea/vomiting 27 (61.4%)
Diarrhea 9 (20.4%)
Abdominal pain 9 (20.4%)
Metabolic 23 (10.9%)
Dyslipidemia,
hypercholesterolemia or
hypertriglyceridemia
11  (47.8%)
Lipodystrophia 8 (34.8%)
Anemia 16 (7.5%)
Hiperbilirubinemia 14 (6.6%)
Skin rash 12 (5.7%)Dear Editor,
The  increasing number of available antiretroviral drugs (ARV)
for  treating HIV-1 infection has promoted an amazing reduc-
tion  on AIDS-associated morbidity and mortality. However,
adverse events are still a frequent ﬁnding in on-treatment
patients, and may  have a negative impact on patient’s quality
of  life, adherence to therapy, and long term health problems.1
In Brazil, we  have only scarce data on the frequency of such
problems,  and we  need to better deﬁne what is the real magni-
tude  of these problems in HIV patients initiating antiretroviral
therapy.
The  present work is a pilot, retrospective cohort study, in
which  we  reviewed clinical charts of 100 patients (75% males)
who  started ARV therapy between 2003 and 2009, in Salvador,
Bahia  state, Brazil. We  recorded the number of ARV regimens
used  by each individual, and the related problems detected
during  patient’s follow up.
Most patients (66%) were  black, as expected for a city with
the  characteristics of Salvador. Mean age was  43 years (range
27–67  years), and 68% were  infected by unprotected homosex-
ual  contact. A total of 212 different ARV regimens were used by
the group during follow up period. We found a high (75%) fre-
quency  of adverse events (AE). Table 1 summarizes the main
safety  problems detected in the study sample (only those AE
with  a frequency equal or higher than 5% were described). Of
note,  patients older than 50 years were more  likely (58%) to
present  AE after starting ARV therapy.
Incidence of AE was  the main reason for changing ARV
drugs  in 53% of cases. The AE signiﬁcantly associated with
switching  therapy were neurological (34%; p = 0.02), gastroin-
testinal  (26%; p = 0.03) and metabolic (10%; p = 0.05). Again,
switching therapy was  more  likely to occur in older patients
(aged  more  than 50 years) than in younger ones.
In the present study, we  detected a high rate of AE in
patients initiating ARV therapy in the city of Salvador, similar
to  that found in other studies.2,3 The high frequency ofMyopathy 8 (3.8%)
neurological and gastrointestinal events was  clearly asso-
ciated  with a higher likelihood of changing the initial ARV
regimen.  Although the small number of cases limits the
overall  reach of our ﬁndings, it provides clear evidence on the
importance  of a careful choice of drugs to compose the ﬁrst
ARV  regimen, in order to avoid the risks of low adherence,
virological failure, and early switch of ARV drugs. It becomes
even  more  important in face of the recent changes observed
in  the Brazilian ofﬁcial recommendations to start therapy
with  a pre-deﬁned regimen, limiting the room for tailoring
the  regimen to an individual patient’s need.
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